161 related articles for article (PubMed ID: 32299084)
21. Patterns of pharmacologic treatment in US patients with acromegaly.
Broder MS; Chang E; Ludlam WH; Neary MP; Carmichael JD
Curr Med Res Opin; 2016 May; 32(5):799-805. PubMed ID: 26609770
[TBL] [Abstract][Full Text] [Related]
22. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
23. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
24. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
[TBL] [Abstract][Full Text] [Related]
25. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for acromegaly.
Chanson P
Expert Opin Emerg Drugs; 2008 Jun; 13(2):273-93. PubMed ID: 18537521
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological approach to the treatment of acromegaly.
Ezzat S
Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
[TBL] [Abstract][Full Text] [Related]
28. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
30. Current pharmacotherapy for acromegaly: a review.
Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
[TBL] [Abstract][Full Text] [Related]
31. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery.
Welsch T; Müssle B; Distler M; Knoth H; Weitz J; Häckl D
Langenbecks Arch Surg; 2016 Nov; 401(7):1027-1035. PubMed ID: 27233242
[TBL] [Abstract][Full Text] [Related]
33. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland.
Störmann S; Schopohl J; Bullmann C; Terkamp C; Christ-Crain M; Finke R; Flitsch J; Kreitschmann-Andermahr I; Luger A; Stalla G; Houchard A; Helbig D; Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):224-233. PubMed ID: 33285601
[TBL] [Abstract][Full Text] [Related]
34. Progress in the formulation and delivery of somatostatin analogs for acromegaly.
Fattah S; Brayden DJ
Ther Deliv; 2017 Oct; 8(10):867-878. PubMed ID: 28944744
[TBL] [Abstract][Full Text] [Related]
35. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
36. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
37. Pasireotide in Acromegaly: A Review.
McKeage K
Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
[TBL] [Abstract][Full Text] [Related]
39. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Mazziotti G; Giustina A
Pituitary; 2010; 13(1):60-7. PubMed ID: 19189218
[TBL] [Abstract][Full Text] [Related]
40. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
Ludlam WH; Anthony L
Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
